早期乳腺癌女性生育力保存中控制性卵巢过度刺激的安全性与有效性:一项系统综述
本系统综述检索MEDLINE、EMBASE和Cochrane图书馆,纳入15项研究,评估早期乳腺癌女性化疗前接受控制性卵巢过度刺激(COH)的安全性和有效性。来曲唑联合COH可抑制雌二醇峰值而不显著降低获卵数,两项前瞻性非随机研究未显示无复发生存率下降。来曲唑5mg每日方案被推荐,GnRH激动剂触发有益。
要点
- 来曲唑联合COH可抑制雌二醇峰值(338-829 pg/ml),不显著降低获卵数。
- 最大研究显示来曲唑+COH组复发6/120(5.0%),未COH组12/217(5.5%),HR 0.77(95%CI 0.28-2.13)。
- 推荐来曲唑5mg每日自第2天起贯穿COH,GnRH激动剂触发有益。
核心结论
- 来曲唑联合COH抑制雌二醇水平而不显著影响获卵数或降低无病生存率。
- 来曲唑5mg每日自第2天起贯穿COH被推荐,因降低雌二醇峰值而不显著降低获卵数。
- GnRH激动剂触发有益,因给药后雌二醇迅速下降且卵巢过度刺激率低于hCG触发,不降低临床妊娠或活产率。
- 他莫昔芬的保护作用尚未评估,理论上可能因其雌激素受体作用而有益。
研究设计与样本
- 系统综述,检索MEDLINE(PubMed)、EMBASE和Cochrane图书馆,限英文,无发表日期限制,最后检索2016年4月。
- 纳入随机对照试验、病例对照和队列研究,报告早期乳腺癌女性COH后死亡/复发主要结局或获卵数和雌二醇峰值次要结局。
- 两项前瞻性非随机研究报告397名乳腺癌女性(149名接受COH)的复发和乳腺癌相关死亡率。
- 十二项研究报告882名接受来曲唑联合COH女性的雌二醇峰值浓度。
- 四项研究比较248名来曲唑联合COH与254名标准COH女性的获卵数。
主要发现
- 共识别1002条记录,15项纳入最终分析。
- 最大研究报告来曲唑+COH组复发6/120(5.0%) vs 未COH组12/217(5.5%),平均随访5.0年 vs 6.9年,复发风险比0.77(95%CI 0.28-2.13)。
- 来曲唑自第2-3天开始可抑制雌二醇峰值至338-829 pg/ml,获卵数无下降。
- 他莫昔芬不抑制雌二醇浓度,但可能通过其对雌激素受体的抑制作用提供保护。
- 因数据不足,无法对COH期间接受他莫昔芬的乳腺癌女性得出结论。
关键数值与推荐
- 推荐来曲唑5mg每日自第2天起贯穿COH,因降低雌二醇峰值而不显著降低获卵数。
- GnRH激动剂触发有益,因给药后雌二醇迅速下降且卵巢过度刺激率低于hCG触发,不降低临床妊娠或活产率。
临床怎么用
- 对早期乳腺癌女性生育力保存,可采用来曲唑5mg每日自第2天起贯穿COH以抑制雌二醇峰值。
- COH中可使用GnRH激动剂触发以降低卵巢过度刺激风险且不降低妊娠或活产率。
- 他莫昔芬在COH中的保护作用尚未评估,理论上可能有益。
局限性
- 关于COH在乳腺癌女性中安全性的任何陈述均基于有限数量的观察性研究。
- 由于伦理和实践原因,高质量证据不太可能获得。
- 现有数据未显示无病生存率下降,但不能排除小效应。
- 乳腺癌遗传特征和受体状态异质,使研究结果难以推广至个体病例。
- COH继发的其他激素水平变化(如雄激素、孕激素或血管内皮生长因子)在乳腺癌女性中的意义尚未量化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can controlled ovarian hyperstimulation (COH) for fertility preservation be effectively conducted in women with breast cancer without worsening their prognosis? SUMMARY ANSWER: COH with co-administration of letrozole suppresses oestradiol levels without significantly impacting oocyte yield or decreasing disease-free survival rates. WHAT IS KNOWN ALREADY: Oestradiol has the capacity to stimulate the proliferation of breast cancer cells. COH can cause oestradiol levels to rise by an order of magnitude above physiological levels. Concern exists regarding the effect of supra-physiological oestradiol levels in women with a recent diagnosis of breast cancer. STUDY DESIGN, SIZE, DURATION: A systematic review of the literature was performed using MEDLINE (PubMed database), EMBASE and the Cochrane Library. The search was restricted to articles written in English. No restrictions regarding the date of publication were applied. Safety was assessed in terms of relapse rates and cancer-related mortality rates. Peak oestradiol concentrations were recorded for different stimulation protocols. Efficacy was measured in terms of the total number of oocytes collected and proportion of mature oocytes. The primary outcome was mortality/recurrence in premenopausal women with Stage I-IIIB breast cancer who underwent COH in the immediate post-operative period, prior to chemotherapy. PARTICIPANTS/MATERIALS, SETTING, METHODS: This is a systematic review of randomized control trials (RCTs), case control and cohort studies reporting on the primary outcome of mortality/recurrence after COH in women with early breast cancer, or secondary outcomes of oocyte yield and peak oestrogen concentration. Owing to the small number of RCTs available, other study types were included. The last electronic search was run in April 2016. Two prospective non-randomized studies reported relapse and breast cancer-related mortality rates in 397 women with breast cancer, of whom 149 underwent COH. Twelve studies reported the peak oestradiol concentrations of 882 women undergoing COH with letrozole co-administration. Four studies compared the oocyte yield of 248 women who underwent COH plus letrozole with 254 women who underwent standard COH. Two studies compared peak oestradiol concentrations and oocyte yield in 61 women who underwent COH with tamoxifen co-administration and 49 women who underwent COH without tamoxifen. One study compared letrozole and tamoxifen co-administration, and another study compared the co-administration of letrozole and anastrozole. MAIN RESULTS AND THE ROLE OF CHANCE: The search identified 1002 records of which 15 were included in the final analysis. There was no evidence of a decline in relapse-free survival rates in the two studies of women with breast cancer who received COH with letrozole co-administration compared with women who did not undergo fertility preservation procedures. The largest of these studies reported recurrences in 6/120 (5.0%) women who received COH plus letrozole compared with 12/217 (5.5%) women who did not undergo COH (mean follow-up 5.0 versus 6.9 years; hazard ratio for recurrence 0.77, 95%CI 0.28-2.13). Conclusions regarding women with breast cancer who received tamoxifen during COH could not be made due to insufficient data. Peak oestradiol concentrations (338-829 pg/ml) were suppressed by letrozole when commenced on Days 2-3, with no decrease in oocyte yield. Tamoxifen does not suppress oestradiol concentrations, but may convey protection via its inhibitory action on the oestrogen receptor. LIMITATIONS, REASONS FOR CAUTION: Any statements regarding the safety of COH in women with breast cancer are based on a limited number of observational studies. High quality evidence is unlikely to become available for ethical and practical reasons. Whilst available data do not indicate a decline in disease-free survival, a small effect cannot be excluded. Breast cancers are heterogeneous in their genetic profile and receptor status, making the results of studies difficult to generalize to individual cases. The implication of alterations in other hormone levels such as androgens, progestins or vascular endothelial growth factor secondary to COH in women with breast cancer has not been quantified. WIDER IMPLICATIONS OF THE FINDINGS: The co-administration of 5 mg of letrozole daily commencing on Day 2 and continuing throughout COH is recommended as it reduces peak oestradiol concentrations without significantly decreasing oocyte yield. The use of a GnRH agonist trigger is beneficial as oestradiol concentrations rapidly decrease post-administration and rates of ovarian hyperstimulation are lower than with an hCG trigger, without a corresponding reduction in clinical pregnancy or live birth rates in cryopreservation cycles. The protective effect of tamoxifen has not been evaluated although theoretically may be of benefit due to its action on the oestrogen receptor. STUDY FUNDING/COMPETING INTEREST(S): None. REGISTRATION NUMBER: None.
引用
- Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017. PMID: 28333356. doi:10.1093/humrep/dex027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。